WallStreetZenWallStreetZen

NYSE: NVS
Novartis Ag Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

NVS past earnings growth

How has NVS's earnings growth performed historically?
Company
-70.21%
Industry
26.31%
Market
36.92%
NVS's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
NVS's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
NVS's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

NVS past revenue growth

How has NVS's revenue growth performed historically?
Company
-1.98%
Industry
12.4%
Market
161.09%
NVS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
NVS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
NVS's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

NVS earnings and revenue history

Current Revenue
$51.8B
Current Earnings
$7.0B
Current Profit Margin
13.4%
NVS's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

NVS Return on Equity

Current Company
11.4%
Current Industry
38.7%
Current Market
176.9%
NVS's Return on Equity (11.4%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when NVS announces earnings.

NVS Return on Assets

Current Company
5.7%
Current Industry
9.5%
NVS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

NVS Return on Capital Employed

Current Company
10.37%
Current Industry
19.4%
NVS's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

NVS vs General Drug Manufacturer Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
NVS$51.83B$20.75B$6.96B+3.61%-0.55%
AZN$45.15B$8.60B$2.04B+15.18%-16.89%
BMY$46.74B$18.03B$6.68B+17.84%+3.75%
AMGN$26.33B$12.41B$6.84B+2.73%+2.36%
PFE$99.68B$38.03B$29.77B+13.69%+26.49%
View Top General Drug Manufacturer Stocks

Novartis Ag Earnings & Revenue FAQ

What were NVS's earnings last quarter?

On Invalid Date, Novartis Ag (NYSE: NVS) reported Q4 2022 earnings per share (EPS) of $0.69, up 90.53% year over year. Total Novartis Ag earnings for the quarter were $1.47 billion. In the same quarter last year, Novartis Ag's earnings per share (EPS) was $7.29.

If you're new to stock investing, here's how to buy Novartis Ag stock.

What was NVS's earnings growth in the past year?

As of Q1 2023, Novartis Ag's earnings has grown -70.21% year over year. This is 96.53 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 26.31%. Novartis Ag's earnings in the past year totalled $6.96 billion.

What was NVS's revenue last quarter?

On Invalid Date, Novartis Ag (NYSE: NVS) reported Q4 2022 revenue of $13.09 billion up 3.22% year over year. In the same quarter last year, Novartis Ag's revenue was $13.52 billion.

What was NVS's revenue growth in the past year?

As of Q1 2023, Novartis Ag's revenue has grown -1.98% year over year. This is 14.38 percentage points lower than the US Drug Manufacturers - General industry revenue growth rate of 12.4%. Novartis Ag's revenue in the past year totalled $51.83 billion.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.